With $36m in seed funding under its belt, Peel Therapeutics is harnessing the power of Darwinian science as it advances a pipeline of cancer and anti-inflammation assets inspired by plant and animal kingdoms.
“What we’re doing may sound like science fiction,” Peel Therapeutics CEO and co-founder Joshua Schiffman told In Vivo. Indeed, it is not every day that industry takes inspiration from elephant genes, traditional Chinese medicines and insect venom.
But Schiffman is confident that Peel can “identify the superpowers found in evolutionary biology” and add “solubility, scalability and bioavailability”...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
